ARTA
IOVA icon

A.R.T. Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

A.R.T. Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-106,184
Closed -$1.01M – 1487
2019
Q1 		$1.01M Buy
+106,184
New +$1.03M 0.06% 479
2018
Q4 		– Sell
-85,082
Closed -$957K – 1483
2018
Q3 		$957K Buy
85,082
+27,181
+47% +$386K 0.04% 597
2018
Q2 		$741K Sell
57,901
-75,096
-56% -$1.1M 0.03% 768
2018
Q1 		$2.25M Buy
+132,997
New +$2.01M 0.09% 333
2015
Q2 		– Sell
-25,549
Closed -$309K – 1579
2015
Q1 		$309K Buy
+25,549
New +$288K 0.01% 1102

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

A.R.T. Advisors's IOVA Position: Q2 2019 in Review

A.R.T. Advisors sold out of Iovance Biotherapeutics (IOVA) in Q2 2019, closing a stake of 106,184 shares — an estimated $1.01M sold.

A.R.T. Advisors first reported a position in IOVA in Q1 2015 and held it in 5 quarters. The position peaked at $2.25M in Q1 2018. 167 funds tracked by Wall St. Rank hold IOVA as of Q2 2019.

  • A.R.T. Advisors reported no remaining Iovance Biotherapeutics position as of Q2 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 106,184 Iovance Biotherapeutics shares in Q2 2019, an estimated $1.01M.
  • A.R.T. Advisors first reported a position in Iovance Biotherapeutics in Q1 2015 and held it in 5 quarters.
  • A.R.T. Advisors's Iovance Biotherapeutics position peaked at $2.25M in Q1 2018.
  • 167 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2019.

Based on A.R.T. Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.